In 2019, the FDA Oncology Center of Excellence (OCE) approved 11 new drugs and biologic agents, 30 supplemental drug and biologic applications, and four biosimilar applications in oncology. These included two landmark approvals involving collaboration among international regulators as part of OCE Project Orbis, as well as the approval of three novel antibody–drug conjugates.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency
Scientific Reports Open Access 06 May 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Food and Drug Administration. Project Orbis. FDA.gov https://www.fda.gov/about-fda/oncology-center-excellence/project-orbis (2019).
Food and Drug Administration. The therascreen PIK3CA RGQ PCR Kit - P190001 and P190004. FDA.gov https://www.fda.gov/medical-devices/recently-approved-devices/therascreen-pik3ca-rgq-pcr-kit-p190001-and-p190004 (2019).
Food and Drug Administration. Oncology Center of Excellence guidance documents. FDA.gov https://www.fda.gov/about-fda/oncology-center-excellence/oncology-center-excellence-guidance-documents (2019).
Blumenthal, G. M. et al. Real-time oncology review and the assessment aid: increasing review efficiency through standardization and earlier data access. focr.org https://www.focr.org/sites/default/files/ROTR%20White%20Paper%201.pdf (2018).
Usdin, S. FDA to Facilitate Access to Unapproved Drugs. biocentury.com https://www.biocentury.com/biocentury/regulation/2018-12-14/how-fda-plans-help-patients-get-expanded-access-unapproved-drugs (2018).
Acknowledgements
The authors would like to thank Kirsten Goldberg for her assistance with editing this manuscript. FDA does not cite publications because we evaluate the source data and base our approvals on the data that are submitted to the Agency (see Related links).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Related links
FDA-approved drugs: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
Supplementary information
Rights and permissions
About this article
Cite this article
Singh, H., Blumenthal, G. & Pazdur, R. Approvals in 2019: international review and a new agnostic molecular entity. Nat Rev Clin Oncol 17, 130–131 (2020). https://doi.org/10.1038/s41571-020-0336-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-020-0336-8
This article is cited by
-
On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency
Scientific Reports (2020)
